BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220713T160000
DTEND;TZID=Europe/Stockholm:20220713T170000
DTSTAMP:20260430T013414
CREATED:20220630T072933Z
LAST-MODIFIED:20220825T090554Z
UID:29536-1657728000-1657731600@senzagen.com
SUMMARY:Webinar: OECD update
DESCRIPTION:Join this live webinar led by our skin sensitization specialist Dr Andy Forreryd to learn the features and benefits of GARDskin and how the method can be used to fill data gaps during regulatory testing and product development. \n \nGARDskin approved by OECD\nWe are delighted to announce that SenzaGen’s GARDskin assay has been adopted by OECD as part of Test Guideline 442E for in vitro skin sensitization\, which is a regulatory breakthrough for the GARD technology. As the first and only genomics and machine learning-based method\, GARDskin has been approved for the third key event\, dendritic cell activation. The scientific data published in the TG confirms the high performance and broad applicability of the method\, bringing new opportunities to the field of in vitro skin sensitization testing. \nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \nSpeakers\n \nRegister now
URL:https://senzagen.com/event/webinar-oecd-update/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/06/LInkedIn-versaler-e1656335357210.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220525T160000
DTEND;TZID=Europe/Stockholm:20220525T170000
DTSTAMP:20260430T013414
CREATED:20220504T140953Z
LAST-MODIFIED:20220627T125525Z
UID:29411-1653494400-1653498000@senzagen.com
SUMMARY:Webinar: Medical devices' principal mode of action by physical means
DESCRIPTION:Case studies on 3D reconstructed human tissues\nThis webinar will showcase the opportunities offered by 3D reconstructed human tissues to demonstrate the physical mode of action of medical devices in line with the requirements and ethical criteria of the EU Medical Devices Regulation (MDR) 2017/745. \n\nKey takeaways\n\nAttendees will gain insights into: \n💡 How the principles of the 3Rs are applied in the MDR’s requirements. \n💡 How 3D reconstructed human tissues become a robust tool to define and demonstrate the principal mode of action of medical devices. \n💡 How to assess on a case by case approach the physical mode of action of medical devices according to their different therapeutic areas. \n  \n \nNew approach methodologies (NAMs) are driving the transition from animal testing to science-based decision-making for human risk assessment in the life sciences. This transition is aligned with EU Directive 2010/63 on the protection of animals used for scientific purposes and the principles of the 3Rs. \nWe’ll illustrate how NAMs are applied in the medical devices sector. The principles of the 3Rs were an important source of inspiration for the MDR.  ISO 10993 describing the Biological Evaluation of medical devices mandates that appropriate and scientifically validated in vitro methods be preferred over in vivo methods.  3D reconstructed human epidermis tissues can be used to assess skin irritation of medical device components and extracts (ISO 10993-23:2021). Additionally\, genomic-based test methods have been demonstrated to be promising solutions for the assessment of the skin sensitization potential of medical devices (ISO 10993-10:2021). \nManufacturers are required to provide scientific proof in their technical file for the qualification of their product as MD (MDCG 2022-5). They need to provide state-of-the-art scientific data regarding the principal mode of action of the MD. By definition\, this should be physical\, mechanical\, or chemical and cannot be pharmacological\, immunological\, or metabolic. As a result\, the demonstration of a physical mode of action became an essential requirement. The film-forming properties and bio-adhesivity of an MD can be demonstrated on 3D reconstructed human tissue models on a case-by-case approach to produce evidence of the MD’s physical mode of action. \nVitroScreen has developed and published an experimental procedure on reconstructed human epidermis for film-forming assessment. With this as a basis\, we propose protocols optimized for each specific therapeutic area by selecting the tissues on which the MD is intended to act and defining a treatment procedure that mirrors realistic conditions of use. We will present case studies based on different formulation types suitable for gastroenterology\, gynecology\, ophthalmology\, oral care\, urology\, and the respiratory tract. \n  \n\nSpeakers\n\n \n \n  \n\nRegister now
URL:https://senzagen.com/event/webinar-medical-devices-principal-mode-of-action-by-physical-means/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/05/Website-banner-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220428T160000
DTEND;TZID=Europe/Stockholm:20220428T170000
DTSTAMP:20260430T013414
CREATED:20220331T075055Z
LAST-MODIFIED:20220627T125547Z
UID:29263-1651161600-1651165200@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen’s 2022 SOT Scientific Session
DESCRIPTION:New GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals\n\n – Skin sensitization: using in vitro tools for quantitative potency assessment as an alternative to the Local Lymph Node Assay\nIn case you missed SenzaGen’s scientific session at this year’s SOT\, here is a new opportunity! \nTogether with guest speakers from Takasago and Sonova\, we will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. New GARD data on agrochemical formulations\, fragrance materials\, medical devices and metals will be presented. \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nAgenda\n \n\nRegister now
URL:https://senzagen.com/event/webinar-recap-on-senzagens-2022-sot-exhibitor-hosted-session/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/03/Recap-webinar-banner-for-website-v5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260430T013414
CREATED:20220224T104229Z
LAST-MODIFIED:20220224T105153Z
UID:28967-1649116800-1649375999@senzagen.com
SUMMARY:in-cosmetics Global
DESCRIPTION:The leading global event for personal care ingredients\nApril 5-7 | Porte de Versailles\, Paris | Booth: P102\nMeet SenzaGen and partners PKDERM\, GenEvolutioN\, WatchFrog and CEHTRA at in-cosmetics Global in Paris to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients!
URL:https://senzagen.com/event/in-cosmetics-global-2/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/02/Incosmeticsglobal-2022_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220327
DTEND;VALUE=DATE:20220401
DTSTAMP:20260430T013414
CREATED:20211209T133110Z
LAST-MODIFIED:20220321T111837Z
UID:28283-1648339200-1648771199@senzagen.com
SUMMARY:2022 SOT
DESCRIPTION:Meet us at the 2022 SOT Annual Meeting & ToxExpo\nBooth #1207 @ San Diego Convention Center\, San Diego\, USA\nAre you attending the 2021 Society of Toxicology Annual Meeting? Come join our hosted session and poster presentations to hear the latest news about GARD™ and how the assays are used for skin sensitization testing. We will also introduce you to how you can use in vitro methods for the biological evaluation of medical devices.  \n\nExhibitor hosted session\n\nMar 29\, 10:30-11:30 EDT\, Room 23A\nNew GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals:\nTogether with guest speakers from Takasago and Sonova\, our Scientific Liaison Dr Andy Forreryd will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. \n  \n \nBook mark the session in SOT’s event calendar: \nSkin Sensitization: Using In Vitro Tools for Quantitative Potency Assessment as an Alternative to the Local Lymph Node Assay \n  \n\nPosters\n\nLive poster sessions on Mar 28\, 9:00-10:45 EDT\n🎫 P460 | Applicability domain of GARDskin\nThe GARDskin assay: Investigation of the applicability domain of indirectly acting haptens  \n🎫 P850 | Joint poster with Sonova\nIn vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices  \n🎫 P846 | Joint poster with Risk Science Consortium\nAbility of the GARD assay to replace the GPMT and the LLNA for assessment of the skin sensitization potential of medical devices  \n 
URL:https://senzagen.com/event/2022-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/SOT-2022_small-narrow-green.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220217T160000
DTEND;TZID=Europe/Stockholm:20220217T170000
DTSTAMP:20260430T013414
CREATED:20211209T154800Z
LAST-MODIFIED:20220204T125454Z
UID:28308-1645113600-1645117200@senzagen.com
SUMMARY:Webinar: Safer Medical Devices - In vitro assays as part of your biological evaluation
DESCRIPTION:In this webinar\, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices\, now offered at our GLP certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR. \nThe webinar will last around 45 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, make sure to register to get access to the recording. \nKey topics\n\nHow you can use in vitro assays for biocompatibility testing of medical devices: cytotoxicity\, skin irritation and sensitization.\nThe broad applicability and high accuracy of the GARD sensitization assay\, supporting both polar and non-polar extraction vehicles (ISO 10993-12).\nUser cases on skin sensitization assessment of medical devices.\n\n \nSpeaker\n \n\nHighly accurate and ethical alternatives \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nOur GLP certified laboratories offer an in vitro biocompatibility package that includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, providing a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human-relevant results with higher accuracy and fewer false-positive results compared to the rabbit model. \nSkin sensitization with GARD™ \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and  10993-10:2021\, thus mimicking the intended use of the device when in contact with skin.  \n\nRegister now
URL:https://senzagen.com/event/webinar-biological-evaluation-of-medical-devices-using-in-vitro-methods/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/Banner-without-logo-Cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220120T160000
DTEND;TZID=Europe/Stockholm:20220120T170000
DTSTAMP:20260430T013414
CREATED:20211209T154427Z
LAST-MODIFIED:20220105T083742Z
UID:28303-1642694400-1642698000@senzagen.com
SUMMARY:Webinar: Why Choose GARD™ for Skin Sensitization Testing?
DESCRIPTION:High performance\, broad applicability\, quantitative potency\n\nJoin us for this webinar to get the latest news about the in vitro GARD assays and how they are used to fill data gaps and address challenges in skin sensitization testing\, such as “difficult-to-test” substances\, quantitative potency assessment\, testing of medical devices and solid materials. \n \nKey topics\n\nAn introduction to GARD: How the genomic and machine learning-based technology works and its applications\nCase studies: “Difficult-to-test” samples such as complex mixtures\, pre/pro- haptens and substances with low water solubility\nCase studies: In vitro skin sensitization assessment of medical devices using both saline and oil as extraction vehicles\nCase studies: In vitro quantitative potency assessment as an alternative to LLNA\n\nThe webinar will last around 40 minutes\, followed by a live Q&A. If you can’t attend the live event\, register now to get access to the recording.  \nSpeakers\n \n \n  \nRegister now
URL:https://senzagen.com/event/webinar-why-choose-gard-for-sensitization-testing-2/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/Webinar-banner-v7-cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211214T160000
DTEND;TZID=Europe/Stockholm:20211214T170000
DTSTAMP:20260430T013414
CREATED:20211209T135308Z
LAST-MODIFIED:20211209T135357Z
UID:28292-1639497600-1639501200@senzagen.com
SUMMARY:SaferWorldbyDesign Webinar: Skin safety assessment according to OECD guidelines
DESCRIPTION:Join our skin sensitization expert Dr Andy Forreryd at this SaferWorldbyDesign webinar & panel discussion to learn more about skin safety assessment. \n  \nRead more and register here \n 
URL:https://senzagen.com/event/saferworldbydesign-webinar-skin-safety-assessment-according-to-oecd-guidelines/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/12/banner1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211202
DTEND;VALUE=DATE:20211203
DTSTAMP:20260430T013414
CREATED:20211115T161609Z
LAST-MODIFIED:20211118T123538Z
UID:28127-1638403200-1638489599@senzagen.com
SUMMARY:New Approach Methodologies for Medical Devices
DESCRIPTION:NAMs for Medical Devices: Use of New Approach Methodologies for the Biological Safety Assessment of Medical Devices \nJoin New Approach Methodology Use for Regulatory Application (NURA) on December 2 to learn how you can use the latest in vitro methods for Biological Safety Assessment of medical devices. Engage with industry experts and the Center for Devices and Radiological Health and learn how to use new approaches for risk assessment in the ISO 10993 series\, including updates to ISO 10993-01\, ISO10993-10\, and ISO 10993-23. \nSpeaker \nRose-Marie Jenvert\, PhD SenzaGen\nIn Vitro Skin Sensitization Testing: Updates in ISO 10993-10\, Validation and Regulatory Acceptance
URL:https://senzagen.com/event/new-approach-methodologies-for-medical-devices/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/11/NURA-Medical-Devices-Training.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211118T160000
DTEND;TZID=Europe/Stockholm:20211118T170000
DTSTAMP:20260430T013414
CREATED:20210930T080606Z
LAST-MODIFIED:20211021T122341Z
UID:27696-1637251200-1637254800@senzagen.com
SUMMARY:Webinar: Safety Testing of Cosmetic Products
DESCRIPTION:An Overview of Established Methods and New Approach Methodologies (NAMs)\nIn this joint webinar\,  we will present an overview of established methods and New Approach Methodologies (NAMs) used in the safety testing of cosmetic products. The webinar will start with a recorded presentation followed by a live Q&A session. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nKey topics and speakers\n \n\nRegister now
URL:https://senzagen.com/event/webinar-safety-testing-of-cosmetic-products/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/09/Webinar-banner-_-light-text-cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211111T160000
DTEND;TZID=Europe/Stockholm:20211111T170000
DTSTAMP:20260430T013414
CREATED:20211011T163155Z
LAST-MODIFIED:20211011T163155Z
UID:27835-1636646400-1636650000@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen's Eurotox Industry Symposium
DESCRIPTION:Filling data gaps in skin sensitization testing: In vitro hazard and potency assessment using GARD\nIn case you missed SenzaGen’s industry symposium at this year’s Eurotox Virtual Congress\, here is a new opportunity! Together with guest speakers from Corteva Agriscience and Essity Hygiene & Health\, we will present customer cases where the in vitro GARD assays have been successfully utilized to fill data gaps in skin sensitization hazard and potency testing. The webinar will last around 50 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, register now to get access to the recording. \n  \n \nAgenda and featured speakers\n \n  \n\nRegister now\n\n 
URL:https://senzagen.com/event/webinar-recap-on-senzagens-eurotox-industry-symposium/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/10/Webinar-cover-Cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211013T160000
DTEND;TZID=Europe/Stockholm:20211013T170000
DTSTAMP:20260430T013414
CREATED:20210906T094522Z
LAST-MODIFIED:20210906T123106Z
UID:27554-1634140800-1634144400@senzagen.com
SUMMARY:Webinar: Safer Medical Devices – In Vitro Assays As Part of a Biological Evaluation
DESCRIPTION:In this webinar\, the speakers will discuss the uses of in vitro assays as a part of the risk assessment and biological evaluation for the following endpoints: cytotoxicity\, skin irritation and skin sensitization. \nKey topics\nThe presentation will introduce biological evaluation and biocompatibility testing of medical devices\, with focus on in vitro assays for skin irritation and skin sensitization now implemented in the ISO 10993-23:2021 and ISO/FDIS 10993-10:2021. For assessment of skin sensitization\, the GARD™-technology will be introduced and the speakers will discuss how it can be used as a part of a biological evaluation. \nThe webinar will conclude with customer cases where in vitro assays\, including GARDskin Medical Device assay and GARDskin Dose-Response\, have been successfully utilized for risk assessment as part of the biological evaluation and for risk-based decision-making in compliance with the principles of the 3Rs throughout the product life cycle. \n  \n \nSpeakers\n  \n\nA highly accurate and ethical alternative \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nThe in vitro biocompatibility package includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, offering a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human relevant results with higher accuracy and less false positive results compared to the rabbit model. \nSkin sensitization with GARD™ \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification-model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and FDIS/ISO 10993-10:2021\, thus mimicking the intended use of the device when in contact with skin. \n\nRegister now
URL:https://senzagen.com/event/webinar-safer-medical-devices-in-vitro-assays-as-part-of-a-biological-evaluation/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/09/Banner-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211013
DTEND;VALUE=DATE:20211015
DTSTAMP:20260430T013414
CREATED:20210826T115835Z
LAST-MODIFIED:20210906T082248Z
UID:27465-1634083200-1634255999@senzagen.com
SUMMARY:Cosmetic 360
DESCRIPTION:The international innovation fair for cosmetic and perfume industry\nOctober 13-14 | Carrousel du Louvre\, Paris | Booth: S4\nMeet SenzaGen and partners PKDerm\, GenEvolutioN\, WatchFrog and CEHTRA at Cosmetic 360\, the international innovation fair for the cosmetic and perfume industry\, to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients. \nOrganised by Cosmetic Valley\, this event will bring together the Cosmetic 360 international trade fair and the annual summit of the French fragrance and cosmetics industry. \n  \n \nBenefit from our joint expertise\nWe look forward to meeting you to discuss our common interests and possible collaboration on safety testing of cosmetics:\n  \n\nSensitization\nIrritation\nPhoto irritation/sensitization\nEndocrine disruptor properties\nDermal absorption\nMOS toxicology risk assessment\nGenotoxicity\n\n  \n \n\n 
URL:https://senzagen.com/event/cosmetic-360/
LOCATION:Paris\, France
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/08/stand_carre_en_4ef9da3d597eb6431934405e8189f76207d8ad64.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210930
DTEND;VALUE=DATE:20211005
DTSTAMP:20260430T013414
CREATED:20210408T090913Z
LAST-MODIFIED:20210930T105113Z
UID:26194-1632960000-1633391999@senzagen.com
SUMMARY:Eurotox
DESCRIPTION:Eurotox 2021 Virtual Congress\n27 September – 1 October\n  \n\n\n\n\n🌎Industry symposium hosted by SenzaGen \nSep 29\, 17.30 – 18.30\n\n\n\n\n\nFilling data gaps in skin sensitization testing: in vitro hazard and potency assessments using GARD \n\nDr Andy Forreryd \nDr Henrik Johansson\n\n\n\n\nGARDskin and GARDpotency: a proof of concept study to investigate the applicability domain for agrochemical formulations \n\nGuest Speaker\nMarco​ Corvaro\, Corteva Agriscience\n\n\n\n\n\nAssessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay \n\nGuest Speaker\nPeter Mohlin\, Essity Hygiene & Health AB\n\n\n\n\n\n\n\n  \n \n🌎Presentation at Session 12 – Symposium\nSep 28\, 16.30 – 18.30\n\n\n\n\n\nGenomics-based platforms in combination with machine learning algorithms enabling well informed and reliable risk assessments for different toxicological endpoints \nSession 12– Symposium: Application of high throughput transcriptomics in mechanism-based chemical safety assessment\nDr Andy Forreryd\n\n\n\n\n\n\n\n\nPosters open for viewing: \n Sep 27 – Oct 1\n\n\n\n# P23-11 \nAbstract ID 140\nQuantitative sensitizing potency assessment using GARDskin Dose-Response\nDr Henrik Johansson\n\n\n# P04-10 \nAbstract ID 164\nApplicability domain of the GARDskin Medical Device test for in vitro skin sensitization testing of medical devices\nDr Rose-Marie Jenvert \n \n\n\n# P04-30 \nAbstract ID 390\nIn vitro assessment of the skin sensitizing potential and potency of epoxy resin monomers and pre-polymer mixtures using the GARD assay\nDr Helge Gehrke\, Eurofins\n\n\n# P23-34 \nAbstract ID 402\nAssessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay\nPeter Mohlin\, Essity
URL:https://senzagen.com/event/eurotox-2/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/04/eurotox2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210916T160000
DTEND;TZID=Europe/Stockholm:20210916T170000
DTSTAMP:20260430T013414
CREATED:20210826T102829Z
LAST-MODIFIED:20210826T142827Z
UID:27453-1631808000-1631811600@senzagen.com
SUMMARY:Webinar: How is GARD used for skin sensitization testing?
DESCRIPTION:User cases on hazard and potency assessment\nGiven the huge interest in our previous webinar on GARD user cases\, we are pleased to offer you a new opportunity to hear how our customers use GARD to fill data gaps in sensitizing hazard and potency assessment of chemicals and medical devices. \n\nKey topics\nWe will provide several user cases on how the GARD assays have been used for skin sensitization testing to demonstrate: \n\nHazard assessment of “difficult-to-test” samples such as complex mixtures and surfactants.\nSensitization information for risk assessment of medical devices and solid materials.\nPotency determination for both CLP classification and product development.\n\nThe webinar should last around 40 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording of this webinar. \nSpeakers\n  \n\nRegister now
URL:https://senzagen.com/event/new-opportunity-how-is-gard-used-for-sensitization-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/08/webinar-banner-cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210902
DTEND;VALUE=DATE:20210903
DTSTAMP:20260430T013414
CREATED:20210315T135907Z
LAST-MODIFIED:20210824T092518Z
UID:25927-1630540800-1630627199@senzagen.com
SUMMARY:WC11
DESCRIPTION:11th World Congress on Alternatives and Animal Use in the Life Sciences\n23 August – 2 September 2021 | Virtual Congress\n  \n\n\n\n\nPosters open for viewing: \n Aug 10 – Sep 2\n\n\n\n# P471 \nAbstract ID 961\nQuantitative sensitizing potency assessment using GARDskin Dose-Response\nDr Henrik Johansson\n\n\n\n\n\n\n\n# P140 \nAbstract ID 334\nThe GARDpotency assay for potency-associated subclassification of chemical skin sensitizers – rationale\, method development and ring trial results of predictive performance and reproducibility\nDr Henrik Johansson\n\n\n\n\n\n\n\n# P146 \nAbstract ID 346\nReliable and truly animal-free skin sensitization testing – adaption of the in vitro GARDskin assay to animal-free conditions\n Dr Andy Forreryd\n\n\n\n\n\n\n\n# P147 \nAbstract ID 348\nHazard assessment of photoallergens using GARDskin\nDr Andy Forreryd\n\n\n\n\n\n\n\n\nTwo dedicated poster sessions for live Q&A:  \nAug 27\,  18.00 – 19.30  ;   Aug 31\,  17.15 – 18.15\n\n\n\n\n\n\n\n\n\n🌎Invited presentation at OECD & EURL ECVAM Joint Session \nAug 30\, 15.00 – 17.00\n\n\n\nAbstract ID 331\n\nTransferability challenges with modern technology and how to overcome them – a case study of the GARD assays from a test method developer’s perspective \nMO-1  S59:  Innovative technologies integrating standardised regulatory test methods: challenges and perspectives \nTheme: Innovative Technologies \n \nDr Henrik Johansson\n\n\n\n 
URL:https://senzagen.com/event/wc11/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/03/WC11-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210601T160000
DTEND;TZID=Europe/Stockholm:20210601T170000
DTSTAMP:20260430T013414
CREATED:20210525T093936Z
LAST-MODIFIED:20210525T094123Z
UID:27136-1622563200-1622566800@senzagen.com
SUMMARY:SaferWorldbyDesign Webinar: A novel in vitro approach for quantitative assessment of skin sensitizing potency
DESCRIPTION:This presentation will introduce GARDskin Dose-Response assay\, a novel approach for the assessment of relative skin sensitizing potency on a continuous scale. \nResults demonstrate that induction of toxicity pathways in GARDskin Dose-Response appears to be highly dose-dependent\, and the lowest concentration required to induce a positive classification in the assay correlates strongly and significantly with both LLNA EC3 and human NOEL values. \nA case study will be used to illustrate how the experimentally derived values from the GARDskin Dose-response assay can be used for CLP potency assessments\, potency rankings of potential candidate molecules\, or as a point of departure for quantitative risk assessment without having to revert to animal experimentation. \nFeatured Speakers\n\nAndy Forreryd\, PhD \nDr Andy Forreryd holds a Master of Science in molecular biotechnology from the Faculty of Engineering LTH at Lund University and a Doctor of philosophy in Immunotechnology from Lund University. He has many years of experience working with in vitro assay development\, genomics\, and machine learning. He is co-developer of the GARD® platform for the assessment of chemical sensitizers and inventor of two patents related to the technology. \n  \nRead more and register here
URL:https://senzagen.com/event/saferworldbydesign-webinar-a-novel-in-vitro-approach-for-quantitative-assessment-of-skin-sensitizing-potency/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210527T160000
DTEND;TZID=Europe/Stockholm:20210527T170000
DTSTAMP:20260430T013414
CREATED:20210330T110020Z
LAST-MODIFIED:20210414T104704Z
UID:26126-1622131200-1622134800@senzagen.com
SUMMARY:Webinar: Skin Sensitizing Potency Assessment: Filling in data gaps
DESCRIPTION:In this webinar you will learn how combining genomics and machine learning provides a highly accurate in vitro method for qualitative and quantitative skin sensitizing potency assessment\, filling in data gaps in safety testing projects. \nThe webinar will last around 30 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, still register to get access to the recording of this webinar. \n  \n \nKey takeaways\n\nHow to use GARD for qualitative and quantitative skin sensitizing potency assessment.\nHow the GARD technology works and why it is highly accurate and human-relevant.\nHow customers across industries use the results for potency ranking of candidate ingredients and early decision-making during product development.\n\n\nFeatured speakers\n \n \n\nRead more and register
URL:https://senzagen.com/event/webinar-filling-in-data-gaps-in-skin-sensitizing-potency-assessment/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/03/80A1838-small.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210428T160000
DTEND;TZID=Europe/Stockholm:20210428T170000
DTSTAMP:20260430T013414
CREATED:20210408T091734Z
LAST-MODIFIED:20210408T092920Z
UID:26198-1619625600-1619629200@senzagen.com
SUMMARY:Tecan webinar series: In vitro technology replacing animal models for skin sensitization testing
DESCRIPTION:Determining if a new cosmetic product\, pharmaceutical ingredient\, or chemical substance is harmful to humans is a key prerequisite for product safety and consumer protection. Traditionally\, skin sensitization testing relied on animal models\, but these approaches are expensive\, time consuming and raise ethical questions\, while only offering limited human relevance and accuracy. SenzaGen has developed a unique\, in vitro approach to sensitization testing\, combining cell biology and flow cytometry with genomics-based screening and machine learning-assisted classifications \nFeatured Speakers\n\nAnna Chérouvrier Hansson leads the business development and sales activities at SenzaGen. With more than 20 years in the life science industry\, she has experience from leading projects within pharma\, medical device and specialised service companies with focus on delivering superior products and solutions. \n\nUlrika Mattson is Senior Application Scientist at SenzaGen. She has a long experience of laboratory work and today she leads projects and studies involving SenzaGen’s proprietary technology GARD for assessment of skin and respiratory sensitizers. Ulrika has experience of Tecan’s equipment at SenzaGen’s laboratory. \n  \nRegister here
URL:https://senzagen.com/event/tecan-webinar-series-in-vitro-technology-replacing-animal-models-for-skin-sensitization-testing/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/04/Tecanwebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210414T160000
DTEND;TZID=Europe/Stockholm:20210414T170000
DTSTAMP:20260430T013414
CREATED:20210325T191550Z
LAST-MODIFIED:20210329T102136Z
UID:26075-1618416000-1618419600@senzagen.com
SUMMARY:Webinar: SenzaGen's 2021 SOT Poster Presentations
DESCRIPTION:In case you missed our poster presentations at this year’s Society of Toxicology Annual Meeting\, here is a new opportunity. Register to get the latest updates on the GARD™ assays and how they can be used to fill in data gaps for skin sensitizing hazard and potency assessment. \n\nThe webinar will last around 30 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, still register to get access to the recording of this webinar. \nPoster presentations:\nApplicability Domain of the GARD™skin Medical Device Test for In Vitro Skin Sensitization Testing of Medical Devices 🏅 (MDCPSS Best Overall Abstract) |By Dr Ron Brown \n  \nQuantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response | By Dr Henrik Johansson \nFeatured speakers\n \n \n  \nRead more and register
URL:https://senzagen.com/event/webinar-senzagens-2021-sot-poster-presentations/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/03/A_Lime_600px-Cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210326
DTEND;VALUE=DATE:20210327
DTSTAMP:20260430T013414
CREATED:20201126T144515Z
LAST-MODIFIED:20210319T083907Z
UID:25617-1616716800-1616803199@senzagen.com
SUMMARY:2021 SOT
DESCRIPTION:Booth #2062\nProgram\nThe official meeting time zone is US Eastern Daylight Time\, UTC -4. Please consult the World Time Zone Map for further guidance regarding the time conversions. \n\n\n\nMarch 16\n\n\n\n\n09:00am-10:00am\nExhibitor Hosted Session\, Booth #2062\n\n\n\n\nIn vitro skin sensitization testing for qualitative and quantitative potency assessment using GARD™\nDr Henrik Johansson\n\n\nMarch 23\n\n\n\n\n1:00pm – 2:45pm\nPoster Board # P323\n\n\n\n\nQuantitative Sensitizing Potency Assessment Using GARD Skin Dose-Response\nDr Henrik Johansson\n\n\n1:00pm – 2:45pm\nPoster Board # P322\n\n\n\n\nGARD Skin and GARD Potency: A Proof of Concept Study to Investigate the Applicability Domain for Agrochemical Formulations\nMarco Corvaro\, Corteva Agriscience\n\n\nMarch 24\n\n\n\n\n11:15am – 1:00pm\nPoster Board # P158\n\n\n\n\nApplicability Domain of the GARDskin Medical Device Test for In Vitro Skin Sensitization Testing of Medical Devices\nDr Rose-Marie Jenvert\n\n\n1:50pm – 2:20pm\nWorkshop 1287\n\n\n\n\nNovel In Vitro Assays for Sensitization Hazard Identification and Risk Assessment: Exploration of Chemical Space and Potential for Classifications of Difficult-to-Test Substances\nDr Andy Forreryd
URL:https://senzagen.com/event/2021-sot/
LOCATION:Virtual Meeting
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2020/11/SOT2021.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210311T160000
DTEND;TZID=Europe/Stockholm:20210311T170000
DTSTAMP:20260430T013414
CREATED:20210216T124016Z
LAST-MODIFIED:20210217T124718Z
UID:23883-1615478400-1615482000@senzagen.com
SUMMARY:Nouvelle session – Cosmetic Safety 3.0 Webinaire France
DESCRIPTION:Webinaire en français (in French)\nParticipez à ce webinaire sur les nouvelles technologies in vitro utilisées pour l’évaluation des produits cosmétiques organisé par PKDerm\, GenEvolutioN et SenzaGen avec la participation de CEHTRA – experts en toxicologie. \nSuite au grand intérêt porté à la précédente édition de notre webinaire Cosmetic 3.0\, nous sommes ravis de vous convier à cette nouvelle session. Le webinaire débutera avec une présentation pré-enregistrée suivie par une session Questions-Réponses en direct. \n  \n \nProgramme\nÉvaluation des produits cosmétiques – pourquoi\, quand et comment? \nEfficacité: pénetration cutanée et inflammation (PKDerm) \nSécurité: toxicologie génétique appliquée aux produits naturels et aux produits de synthèse (GenEvolutioN) \nSécurité: sensibilisation cutanée\, le test génomique GARDskin (SenzaGen) \nSession questions-réponses \nConférenciers\n\n\nDr Hanan Osman-Ponchet\, Founder CEO & CSO\, PKDerm\n\nHanan Osman Ponchet est titulaire d’une maîtrise en toxicologie et pharmacologie ainsi que d’un doctorat en biochimie\, biologie céllulaire et moléculaire. Riche d’une expérience de 20 ans en développement pharmaceutique chez Sanofi et en charge du développement de nouveaux outils in vitro au sein de Galderma\, elle est la fondatrice et PDG de la société PKDERM spécialisée dans les tests in vitro pour évaluer l’efficacité et la sécurité des produits cosmétiques et pharmaceutiques. \n\n\nFrancis Finot\, Co-Founder\, GenEvolutioN\n\nFrancis Finot est titulaire d’un Master en pharmacologie cellulaire et toxicologie. Fort d’une longue carrière dans l’industrie pharmaceutique chez Sanofi et en tant que directeur d‘études chez Covance\, il est expert dans le domaine de la génotoxicité et de la sécurité des produits chimiques\, cosmétiques et pharmaceutiques. Francis est co-fondateur et président de GenEvolutioN\, une société créée en 2017\, dédiée à l’expertise en toxicologie génétique et toxicologie in vitro utilisant des nouveaux modèles de cellules humaines. \n\n\nDr Clarisse Bavoux\, Toxicologist\, Regulatory Responsible\, CEHTRA\n\nClarisse BAVOUX est pharmacienne\, titulaire d’un DEA en Toxicologie et d’un doctorat en biologie de l’université Toulouse III. Elle est inscrite au registre européen des toxicologues (ERT) depuis 2012. Clarisse a exercé la toxicologie réglementaire à l’INRS\, à l’AFSSA\, puis à l’ANSM. Depuis 2011\, elle assure le rôle d’évaluateur de la sécurité pour différentes sociétés et tous types de produits cosmétiques. Chez CEHTRA depuis 2017\, elle coordonne l’activité de conseil du développement de l’ingrédient ou du produit cosmétique à la rédaction du rapport final\, jusqu’au suivi du produit lors de sa commercialisation. \n\n\nAnna Chérouvrier Hansson\, VP Business Development\, SenzaGen\n\nAnna Chérouvrier Hansson est diplômée de l’école de commerce de Reims et titualire d’une maîtrise en affaires européennes de l’Université de Lund (Suède). Depuis plus de vingt ans\, elle a occupé des postes en marketing\, ventes et stratégie commerciale au sein de l’industrie des sciences de la vie. En charge du développement d’affaires\, elle est responsable pour les activités commerciales de la société SenzaGen. Francophone\, elle gère également les activités déployées avec nos partenaires français.
URL:https://senzagen.com/event/cosmetic-safety-3-0-webinaire-france-in-french-en-francais/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/02/cropped-banner-v1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210225T160000
DTEND;TZID=Europe/Stockholm:20210225T170000
DTSTAMP:20260430T013414
CREATED:20210209T094609Z
LAST-MODIFIED:20210209T094609Z
UID:25771-1614268800-1614272400@senzagen.com
SUMMARY:Webinar: How is GARD™ used for sensitization testing?
DESCRIPTION:User cases on hazard and potency assessment\nJoin us for this free webinar to get the latest news about the in vitro GARD™ assays and how they are used across various industries to fill data gaps in sensitizing hazard and potency assessment of chemicals and medical devices. \n\nKey topics\nWe will provide several user cases on how the GARD assays have been used for skin sensitization testing to demonstrate: \n\nHazard assessment of “difficult-to-test” samples such as complex mixtures and surfactants.\nSensitization information for risk assessment of medical devices and solid materials.\nPotency determination for both CLP classification and product development.\n\nThe webinar should last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording of this webinar. \nFeatured speaker\nRose-Marie Jenvert\, PhD Product Manager GARD applications\, SenzaGen AB \nDr Jenvert is responsible for managing new GARD applications and supporting customer needs with our GARD technology for skin and respiratory sensitization testing. She has extensive knowledge in biocompatibility testing of medical devices and acts as an expert in ISO/TC194 WG8\, updating the standards for skin sensitization and skin irritation (ISO 10993-10 and -23). \n  \nRead more and register
URL:https://senzagen.com/event/webinar-how-is-gard-used-for-sensitization-testing/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/02/Webinar-how-is-GARD-used-20210209-cropped-v2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210127T160000
DTEND;TZID=Europe/Stockholm:20210127T164500
DTSTAMP:20260430T013414
CREATED:20210112T153543Z
LAST-MODIFIED:20210112T153543Z
UID:25716-1611763200-1611765900@senzagen.com
SUMMARY:Webinar: Why choose GARD™ for sensitization testing?
DESCRIPTION:In vitro\, high accuracy\, broad applicability\nJoin this free webinar to learn how the GARD™ assays\, based on genomics and machine learning\, provide a highly accurate method for skin sensitization hazard and potency assessment of chemicals\, including “difficult-to-test” substances. \n\n\nKey topics:\n\nAn introduction to the prediction model\, genomics and machine learning technology\nThe broad applicability and high accuracy of the GARD assays\nSeveral applications and case studies\n\nThe webinar will last around 30 minutes\, followed by a live Q&A. If you can’t attend the live event\, register now to get access to the recording of this webinar. \n  \nFeatured speakers\nAndy Forreryd\, PhD\, Scientific Liaison\, SenzaGen                          Henrik Johansson\, PhD\, Chief Scientist\, SenzaGen \nRead more and register
URL:https://senzagen.com/event/webinar-why-choose-gard-for-sensitization-testing/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/01/Webinar-Why-choose-GARD-2021-01-27-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20201201T190000
DTEND;TZID=Europe/Stockholm:20201202T233000
DTSTAMP:20260430T013414
CREATED:20200904T081245Z
LAST-MODIFIED:20201029T072034Z
UID:24701-1606849200-1606951800@senzagen.com
SUMMARY:STC Symposium 2020
DESCRIPTION:Dec. 1st at 1:10pm EDT \nAs part of the “Sensitization: Skin & Beyond” science panel\, Dr. Andy Forreryd at SenzaGen will be presenting a talk titled: “The GARD Platform for Skin and Respiratory Sensitization Testing: Practical Applications and Case Studies”. \n  \nDon’t miss Andy’s talk and register today!
URL:https://senzagen.com/event/stc-symposium-2020/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2019/11/stc1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20201126T130000
DTEND;TZID=Europe/Stockholm:20201126T160000
DTSTAMP:20260430T013414
CREATED:20200922T090609Z
LAST-MODIFIED:20201118T124806Z
UID:24863-1606395600-1606406400@senzagen.com
SUMMARY:Workshop: In vitro methods in practice
DESCRIPTION:This day is offering a theoretical base with different lectures on research forefront and financing opportunities. The workshop originally included a practical session on site\, but due to the covid-19 situation this session must be postponed. \nResearchers from different universities\, research institutes and companies are participating in the program\, that will last from 1 PM to 4 PM (Central European Time)\, 13-16 (Swedish time). The entire program will be held in English. \nRegister\nRegister for the workshop on November 26th \nProgram\nWelcome – the Swedish 3Rs Center \nIn vitro methods as animal replacements\n\nAn animal free human tumour outside the body for testing of potential anti-cancer compounds\, Stina Oredsson\, Lund University\nMoving away from animal experimentation for acute inhalation toxicity testing\, Emelie Da Silva\, National Research Centre for Working Environment\, Denmark\n\nAnimal free allergy testing using genomics and AI\, Olivia Larne\, Senzagen \n\n\nState-of-the-art in vitro techniques\n\nMicromachined 3D culture scaffolds\, Maria Tenje\, Uppsala University\nMicrofluidic single-cell technologies for disease modeling and drug discovery\, Samareh Gharaei\, Fluicell\nGood in vitro method practices\, Kristina Fant\, RISE
URL:https://senzagen.com/event/workshop-in-vitro-methods-in-practice/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2020/09/3R-logotyp-höger-bättre.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20201116T080000
DTEND;TZID=Europe/Stockholm:20201116T170000
DTSTAMP:20260430T013414
CREATED:20200904T074150Z
LAST-MODIFIED:20201115T183357Z
UID:24697-1605513600-1605546000@senzagen.com
SUMMARY:ACT 2020 Annual Meeting
DESCRIPTION:Monday November 16\, 2020 \n\n\n\n5:00 PM–6:30 PM EST\nVirtual Poster Session: \nDose-Response Analysis in GARD for Assessment of Skin Sensitizer Potency \nApplicability of GARDskin for Accurate Assessment of Challenging Substances in the Context of Skin Sensitization Testing
URL:https://senzagen.com/event/act-2020-annual-meeting/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2020/09/act_am20_logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201030
DTEND;VALUE=DATE:20201031
DTSTAMP:20260430T013414
CREATED:20201014T092354Z
LAST-MODIFIED:20201014T092425Z
UID:25379-1604016000-1604102399@senzagen.com
SUMMARY:NURA 2020 Virtual Symposium
DESCRIPTION:New Approach Methodology Use for Regulatory Application (NURA) in collaboration with the Association for the Advancement of Alternatives Assessment (A4) is hosting two half day trainings to explore practical solutions for the safety assessment of cosmetics and consumer products. Lectures\, discussions\, and demonstrations will help attendees evaluate the advantages of new nonanimal approaches and apply them to a range of consumer and occupational health needs. \nFriday\, October 30\, 2020  \n\n\n\n9:55 am\nThe GARDskin Assay for Skin Sensitization Hazard Identification and Quantitative Potency Assessments: Practical Applications and Case Studies\nAndy Forreryd\, SenzaGen\n\n\n\nRegister for the NURA Short Courses on the Symposium registration page.
URL:https://senzagen.com/event/nura-2020-virtual-symposium/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2020/10/20574-TOX-NURA-for-Consumer-Products-Training-Graphic_FB_Twitter.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201029
DTSTAMP:20260430T013414
CREATED:20200904T073758Z
LAST-MODIFIED:20201014T104011Z
UID:24694-1603843200-1603929599@senzagen.com
SUMMARY:BioInterface 2020 – Workshop & Symposium
DESCRIPTION:Wednesday\, October 28\, 2020 \n\n\n\n\n\n\n\n\n11:05 a.m. PT \n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\nJoshua Schmidt\, SenzaGen\, Inc.\n“Leveraging in vitro to forecast in vivo success”
URL:https://senzagen.com/event/biointerface-2020-workshop-symposium/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2020/09/logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20201021T160000
DTEND;TZID=Europe/Stockholm:20201021T170000
DTSTAMP:20260430T013414
CREATED:20200911T144921Z
LAST-MODIFIED:20200921T162913Z
UID:24756-1603296000-1603299600@senzagen.com
SUMMARY:Webinar: Safer Medical Devices
DESCRIPTION:In Vitro Skin Sensitization Testing with Human Relevance and High Accuracy\nIn this webinar you will learn how combining genomics and machine learning provides a highly accurate in vitro method for assessment of skin sensitization hazard in medical device extracts\, prepared according to ISO 10993-12. \n\n\nWhat You Will Learn\nAttendees will gain insights into: \n\nHow GARD™skin Medical Device works and why it is highly accurate and human-relevant\nHow to predict skin sensitizing hazard of materials by testing extractables directly using extraction solvents in accordance with ISO 10993:12\nHow customers use the study results in different stages of the product life cycle\, for safer products and in line with the 3Rs\n\n\nWho Should Attend?\nThis webinar will benefit professionals working in the medical device industry\, including: \n\nDecision Makers\nSafety Specialists\nBiocompatibility Experts\nToxicologists\n\nThis will also be relevant to consultant companies and CROs specializing in biological evaluation and biocompatibility testing.   \n  \nSpeakers\n            \n\n\nDr Rose-Marie Jenvert:   Product Manager GARD applications\n\n\nDr Joshua Schmidt:   Business Development Director-Americas\n\n\n  \nRead more and register
URL:https://senzagen.com/event/webinar-safer-medical-devices-in-vitro-skin-sensitization-testing-with-human-relevance-and-high-accuracy/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2020/09/Banner-cropped-1.png
END:VEVENT
END:VCALENDAR